Stock Ratings / Health Care / KYMR / forecast

LLY (72) JNJ (66) ABBV (71) UNH (70) ⌘ Pro Terminal →

Kymera Therapeutics Inc. (KYMR) 12-Month Stock Forecast & Price Target Cone

$122.60 +0.07% NASDAQ • Public Delayed / 60s Snapshot

Kymera Therapeutics Inc. (KYMR) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (57/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+58.8% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.

ROARABLE D+ • SELL / AVOID Cap $10.19B

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-0.4% Base Target

WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($2.4M)

46% PutsMax Pain: $120.00

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your KYMR Position Size: $10,000

Shares at $122.60: 81.6 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $95.20

$7,765

$-2,235 (-22.3%)

12M Consensus BaseTarget $122.05

$9,955

$-45 (-0.4%)

12M Bull Case BreakoutTarget $144.02

$11,747

+$1,747 (+17.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$127	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$135	69%	B
JP MorganUS Large-Cap Research	SELL	$109	58%	C

🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk

Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring KYMR)

✓Live walkthrough of KYMR's RQD Radar, SEC cash-conversion gap & downside levels
✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
✓Includes instant 24/7 email alert whenever any of your stocks flip to Red

RQD INSIDER CLUB UPGRADE$49/YEAR

Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?

🤖 Try AI Indicator Builder ($49/yr VIP) →$100K Arena

KYMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +56.20%▲ RESISTANCE BREAKOUT

2026-10-30O $122.6H $127.3L $117.3C $126.6VOL 1.59M

RES: $125.4SUP: $102.6SMA50: $114.9SMA200: $96.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KYMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KYMR Butterfly Map → + Track KYMR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. -16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KYMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KYMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KYMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

KYMR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is KYMR's 12-month stock price target?

Kymera Therapeutics Inc. (KYMR) carries a 12-month consensus base price target of $122.05 (-0.4% from $122.60), with a bull-case target of $144.02 and a bear-case floor of $95.2.